ENIMMUNE CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.1 TWD | -0.44% |
|
+2.87% | -9.07% |
| Mar. 13 | Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2021 | 110M 3.37M | Sales 2022 | 188M 5.79M | Capitalization | 4.02B 124M |
|---|---|---|---|---|---|
| Net income 2021 | -47M -1.44M | Net income 2022 | -248M -7.62M | EV / Sales 2021 | 18.4 x |
| Net cash position 2021 | 342M 10.5M | Net cash position 2022 | 457M 14.05M | EV / Sales 2022 | 18.9 x |
| P/E ratio 2021 |
-49.9
x | P/E ratio 2022 |
-15.7
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 31.48% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.44% | ||
| 1 week | +2.87% | ||
| Current month | +0.44% | ||
| 1 month | +2.25% | ||
| 3 months | -8.95% | ||
| 6 months | -6.32% | ||
| Current year | -9.07% |
1 week
32.80
34.50
1 month
31.4035.25
Current year
31.4038.50
1 year
31.4055.50
3 years
31.40100.00
5 years
14.49125.00
10 years
14.49125.00
| Managers | Title | Age | Since |
|---|---|---|---|
Che Wei Chang
CEO | Chief Executive Officer | - | 17-06-07 |
Chung Cheng Liu
CHM | Chairman | - | 14-01-01 |
Ching Fen Yang
CTO | Chief Tech/Sci/R&D Officer | - | 14-07-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chung Chi Li
BRD | Director/Board Member | - | 20-06-16 |
Che Wei Chang
CEO | Chief Executive Officer | - | 17-06-07 |
Chung Cheng Liu
CHM | Chairman | - | 14-01-01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 34.1 | -0.44% | 42 956 |
| 24-04-22 | 34.25 | +3.32% | 70,358 |
| 24-04-19 | 33.15 | -0.75% | 51,911 |
| 24-04-18 | 33.4 | -1.76% | 28,272 |
| 24-04-17 | 34 | +4.62% | 102,467 |
End-of-day quote Taipei Exchange, April 22, 2024
More quotes
ENIMMUNE CORP. is a Taiwan-based biotechnology new drug company mainly engaged in the development, produce and distribution of new drugs. The Company's new drug products include biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The Company mainly conducts drug testing business, biotechnology service business, international trade business, western medicine wholesale and retail business. The product is Tuberculin PPD.
| 1st Jan change | Capi. | |
|---|---|---|
| -9.07% | 69.04M | |
| -0.35% | 103B | |
| +3.50% | 96.73B | |
| +1.66% | 21.31B | |
| -16.11% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -23.06% | 13.68B | |
| +6.75% | 13.44B | |
| +23.07% | 10.98B |
- Stock Market
- Equities
- 6564 Stock
